Loading...
In 2013, AstraZeneca faced a $6 billion problem: the patent on Nexium, its blockbuster acid-reflux drug, was expiring. Rather than invest in novel drug discovery, the company deployed a playbook perfected across the industry. First, it filed 73 patent claims on minor variations—new coatings, different dosage forms, combination formulations—a strategy called 'evergreening' that extended monopoly pricing years beyond the original patent. Nexium itself was already an evergreen: a near-identical molecule to its predecessor Prilosec, repositioned as a 'new' drug when Prilosec's patent expired in 2001. Simultaneously, the pharmaceutical industry spent $350 million annually lobbying Congress—more than any other sector, employing roughly 1,500 lobbyists, nearly three per member of Congress. In ...
Popular framing: Pharmaceutical companies charge too much because executives are greedy and politicians are corrupt; fixing drug prices requires better leadership and stronger ethics enforcement. It's not 'cheating'—it's exactly what the current 'Incentives' of the US patent system tell companies to do.
Structural analysis: Pharmaceutical rent-seeking is a stable equilibrium produced by the interaction of patent law, lobbying investment returns, regulatory capture, and insurance-mediated price insensitivity. Concentrated beneficiaries rationally outspend diffuse losers in the political process, generating rules (MMA no-negotiation) that protect the rents that fund further rule-making. Evergreening is not a workaround but an institutionalized strategy legible to all actors including regulators. The 'Principal-Agent' problem of doctors—AstraZeneca 'educates' doctors to prescribe the 'New' brand (Nexium) even though the 'Old' generic (Prilosec) is identical and cheaper.
The personalization of a structural problem (blaming executives and politicians rather than incentive architectures) systematically misdirects reform energy toward personnel changes that leave the equilibrium intact. Understanding rent-seeking and public choice theory reveals why the same outcomes recur across different firms, different Congresses, and different decades — and why only structural interventions (negotiating authority, patent reform, prize models) can shift the equilibrium rather than merely rotating its beneficiaries.
